Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Bayer announced the premature termination of a significant late-stage trial for an experimental anti-clotting drug. The trial was halted due to the drug's inferior performance when compared to Bristol-Myers Squibb and Pfizer's well-established Eliquis in preventing strokes among high-risk patients.
The development dealt a major blow to the embattled German pharmaceutical giant and raised concerns about the fate of its most promising medium-term project, observed Reuters.
Setback for Bayer Amidst Ongoing Challenges
The trial's halt, following the recommendation of independent trial supervisors, represents yet another setback for Bayer. Yahoo noted that the company has been grappling with a weak herbicide business, mounting debt, and the burden of U.S. lawsuits related to the alleged carcinogenic effects of its widely-used Roundup weedkiller.
Taking the helm as the new CEO, Bill Anderson intends to explore options to revitalize Bayer's battered share price. Efforts include potentially dividing the company into separate entities and streamlining management decision-making through the reduction of management positions.
Bayer will conduct a comprehensive analysis of the trial's data following its discontinuation. Known as OCEANIC-AF, the trial was initiated in August 2022.
The company stated that the trial's safety data remained consistent with prior studies. While this trial was halted, the independent supervisors recommended continuing a separate phase III trial named OCEANIC-STROKE.
This trial aims to evaluate the efficacy of asundexian in preventing recurring strokes among participants who have already experienced one.
Bayer’s Ambitious Goals and Implications
Bayer had set an ambitious goal for asundexian, aiming to generate over 5 billion euros in peak annual sales. This objective sought to compensate for declining revenue from one of Bayer's pharmaceutical best-sellers, the blood thinner Xarelto.
The patent protection for Xarelto in key European markets is set to expire in 2026. Consequently, the trial's termination also poses a setback for Stefan Oelrich, the head of Bayer's pharmaceutical unit. Oelrich had relied on asundexian's success to drive significant expansion in the United States market, the largest pharmaceutical market globally.
In contrast to its partnership on the Xarelto franchise, where Bayer shared development costs with Johnson & Johnson and ceded most of the U.S. market, Bayer embarked on the asundexian studies independently. The company had prepared to make substantial investments in U.S. marketing and distribution.
Bayer's stock price has fluctuated due to the challenges it faces, and concerns among shareholders have escalated.
Photo: Bayer Newsroom
